Clinical Application and Pharmacodynamic Monitoring of Apixaban in a Patient with End-Stage Renal Disease Requiring Chronic Hemodialysis

Pharmacotherapy

Volumn 36, Issue 11, 2016, Pages e166-e171

  Kufel, Wesley D ^a   Zayac, Adam S ^b   Lehmann, David F ^b   Miller, Christopher D ^a  

^a University Hospital   (United States)

^b State University of New York Upstate Medical University: College of Medicine   (United States)

Author keywords

anticoagulation; antifactor Xa monitoring; apixaban; calciphylaxis; end stage renal disease; hemodialysis; renal dosing; warfarin

Indexed keywords

AMMONIA; APIXABAN; BLOOD CLOTTING FACTOR 10A; CREATININE; ENOXAPARIN; FAMOTIDINE; FENTANYL; FLUDROCORTISONE; FLUTICASONE; LACTULOSE; LOW MOLECULAR WEIGHT HEPARIN; MIDODRINE; NITROGEN; NYSTATIN; PARACETAMOL; RECOMBINANT ERYTHROPOIETIN; UREA; WARFARIN; ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 10A INHIBITOR; PYRAZOLE DERIVATIVE; PYRIDONE DERIVATIVE;

ADULT; AFRICAN AMERICAN; AMMONIA BLOOD LEVEL; ANTICOAGULANT THERAPY; ARTICLE; ATRIAL FIBRILLATION; BLOOD TRANSFUSION; CALCINOSIS; CARDIOPULMONARY ARREST; CASE REPORT; CORONARY ARTERY DISEASE; CREATININE BLOOD LEVEL; DEATH; DIGITAL RECTAL EXAMINATION; DRUG BLOOD LEVEL; DRUG SURVEILLANCE PROGRAM; DRUG WITHDRAWAL; END STAGE RENAL DISEASE; EVENING DOSAGE; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEPARIN INDUCED THROMBOCYTOPENIA; HOSPITAL READMISSION; HUMAN; HUMAN TISSUE; HYPERLIPIDEMIA; HYPERTENSION; INTERNATIONAL NORMALIZED RATIO; MIDDLE AGED; MORBID OBESITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OCCULT BLOOD TEST; PAIN; POSITIVE END EXPIRATORY PRESSURE; RECTUM HEMORRHAGE; RENAL REPLACEMENT THERAPY; RISK BENEFIT ANALYSIS; SEPTIC SHOCK; SKIN BIOPSY; SLEEP DISORDERED BREATHING; UREA NITROGEN BLOOD LEVEL; CHEMICALLY INDUCED; DRUG MONITORING; FATALITY; HEMODIALYSIS; KIDNEY FAILURE, CHRONIC; PROCEDURES;

ANTICOAGULANTS; ATRIAL FIBRILLATION; DRUG MONITORING; FACTOR XA INHIBITORS; FATAL OUTCOME; FEMALE; GASTROINTESTINAL HEMORRHAGE; HUMANS; KIDNEY FAILURE, CHRONIC; MIDDLE AGED; PYRAZOLES; PYRIDONES; RENAL DIALYSIS; WARFARIN;

EID: 84995380353     PISSN: 02770008     EISSN: 18759114     Source Type: Journal    
DOI: 10.1002/phar.1836     Document Type: Article

References (33)

1. Verbeeck RK, Musuamba FT. Pharmacokinetics and dosage adjustment in patients with renal dysfunction. Eur J Clin Pharmacol 2009;65(8):757–73.
2. Dreisbach AW, Lertora JJ. The effect of chronic renal failure on drug metabolism and transport. Expert Opin Drug Metab Toxicol 2008;4(8):1065–74.
3. January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol 2014;64(21):e1–76.
4. Ribic CM, Clase CM. ACP Journal Club: review: in renal impairment, apixaban reduces, or does not increase, bleeding compared with other anticoagulants. Ann Intern Med 2015;162(8):JC3.
5. Pathak R, Pandit A, Karmacharya P, et al. Meta-analysis on risk of bleeding with apixaban in patients with renal impairment. Am J Cardiol 2015;115(3):323–7.
6. Eliquis (apixaban) [package insert]. Princeton, NJ: Bristol-Myers Squibb; 2014.
7. Deal EN, Pope H, Ross W. Apixaban use among patients with severe renal impairment. Ann Pharmacother 2014;48(12):1667.
8. Saifan C, Saad M, El-charabaty E, El-sayegh S. Warfarin-induced calciphylaxis: a case report and review of literature. Int J Gen Med 2013;6:665–9.
9. Cadavid JC, Divietro ML, Torres EA, Fumo P, Eiger G. Warfarin-induced pulmonary metastatic calcification and calciphylaxis in a patient with end-stage renal disease. Chest 2011;139(6):1503–6.
10. Hafiji J, Deegan P, Brais R, Norris P. Warfarin-induced calciphylaxis successfully treated with sodium thiosulphate. Australas J Dermatol 2013;54(2):133–5.
11. Hayashi M, Takamatsu I, Kanno Y, et al. A case-control study of calciphylaxis in Japanese end-stage renal disease patients. Nephrol Dial Transplant 2012;27(4):1580–4.
12. Brandenburg VM, Kramann R, Specht P, Ketteler M. Calciphylaxis in CKD and beyond. Nephrol Dial Transplant 2012;27(4):1314–8.
13. Bae GH, Nambudiri VE, Bach DQ, et al. Rapidly progressive nonuremic calciphylaxis in the setting of warfarin. Am J Med 2015;128(10):e19–21.
14. Chacon G, Nguyen T, Khan A, Sinha A, Maddirala S. Warfarin-induced skin necrosis mimicking calciphylaxis: a case report and review of the literature. J Drugs Dermatol 2010;9(7):859–63.
15. Asobie N, Wong E, Cook MG. Calciphylaxis in a diabetic patient provoked by warfarin therapy. Clin Exp Dermatol 2008;33(3):342–4.
16. Banerjee C, Woller SC, Holm JR, Stevens SM, Lahey MJ. Atypical calciphylaxis in a patient receiving warfarin then resolving with cessation of warfarin and application of hyperbaric oxygen therapy. Clin Appl Thromb Hemost 2010;16(3):345–50.
17. Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on atrial fibrillation. Chest 2010;137(2):263–72.
18. Pisters R, Lane DA, Nieuwlaat R, De vos CB, Crijns HJ, Lip GY. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest 2010;138(5):1093–100.
19. Wang X, Tirucherai G, Marbury TC, et al. Pharmacokinetics, pharmacodynamics, and safety of apixaban in subjects with end-stage renal disease on hemodialysis. J Clin Pharmacol 2016;56(5):628–36.
20. Ikeda K, Tachibana H. Clinical implication of monitoring rivaroxaban and apixaban by using anti-factor Xa assay in patients with non-valvular atrial fibrillation. J Arrhythmia 2016;32(1):42–50.
21. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30(2):239–45.
22. Granger CB, Alexander JH, Mcmurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011;365(11):981–92.
23. Chang M, Yu Z, Shenker A, et al. Effect of renal impairment on the pharmacokinetics, pharmacodynamics, and safety of apixaban. J Clin Pharmacol 2016;56(5):637–45.
24. Dias C, Moore KT, Murphy J, et al. Pharmacokineitcs, pharmacodynamics, and safety of single-dose rivaroxaban in chronic hemodialysis. Am J Nephrol 2016;43(4):229–36.
25. Xarelto (rivaroxaban) [package insert]. Titusville, NJ: Janssen Pharmaceuticals, Inc; 2016.
26. Skeppholm M, Al-aieshy F, Berndtsson M, et al. Clinical evaluation of laboratory methods to monitor apixaban treatment in patients with atrial fibrillation. Thromb Res 2015;136(1):148–53.
27. Frost C, Song Y, Barrett YC, et al. A randomized direct comparison of the pharmacokinetics and pharmacodynamics of apixaban and rivaroxaban. Clin Pharmacol 2014;6:179–87.
28. Barrett YC, Wang Z, Frost C, Shenker A. Clinical laboratory measurement of direct factor Xa inhibitors: anti-Xa assay is preferable to prothrombin time assay. Thromb Haemost 2010;104(6):1263–71.
29. Cuker A, Siegal DM, Crowther MA, Garcia DA. Laboratory measurement of the anticoagulant activity of the non-vitamin K oral anticoagulants. J Am Coll Cardiol 2014;64(11):1128–39.
30. Gouin-thibault I, Flaujac C, Delavenne X, et al. Assessment of apixaban plasma levels by laboratory tests: suitability of three anti-Xa assays. A multicentre French GEHT study. Thromb Haemost 2014;111(2):240–8.
31. Wendte J, Voss G, Vanoverschelde B. Influence of apixaban on antifactor Xa levels in a patient with acute kidney injury. Am J Health Syst Pharm 2016;73(8):563–7.
32. Osanai H, Ajioka M, Masutomi T, et al. Measurement of anti-factor Xa activity in patients on apixaban for non-valvular atrial fibrillation. Circ J 2015;79(12):2584–90.
33. Becker RC, Yang H, Barrett Y, et al. Chromogenic laboratory assays to measure the factor Xa-inhibiting properties of apixaban—an oral, direct and selective factor Xa inhibitor. J Thromb Thrombolysis 2011;32(2):183–7.